Carrier screening in preconception consultation in primary care
- PMID: 22183783
- PMCID: PMC3419291
- DOI: 10.1007/s12687-011-0071-z
Carrier screening in preconception consultation in primary care
Abstract
Discussing carrier screening during preconception consultation in primary care has a number of advantages in terms of promoting autonomy and enabling the greatest range of reproductive choices. For those with a family history of an inherited condition, this ought to be a routine discussion; however, this can be expanded to include the wider population, especially for those conditions for which carrier frequencies are considered relatively common. There is published literature from around the world regarding experiences with carrier screening in primary care for cystic fibrosis, haemoglobinopathies, fragile X syndrome, Tay-Sachs disease and spinal muscular atrophy, although many of these have tended to focus on consultations during rather than before pregnancy. Overall, these studies reveal that population carrier screening is well received by the participants with apparent minimal psychosocial harms; however, challenges exist in terms of approaches to ensure couples receive adequate information to make personally relevant decisions and for ongoing health professional engagement.
Similar articles
-
Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing.J Obstet Gynaecol Can. 2016 Aug;38(8):742-762.e3. doi: 10.1016/j.jogc.2016.06.008. J Obstet Gynaecol Can. 2016. PMID: 27638987
-
Clinical validity and utility of preconception expanded carrier screening for the management of reproductive genetic risk in IVF and general population.Hum Reprod. 2021 Jun 18;36(7):2050-2061. doi: 10.1093/humrep/deab087. Hum Reprod. 2021. PMID: 34021342
-
Interest in expanded carrier screening among individuals and couples in the general population: systematic review of the literature.Hum Reprod Update. 2020 Apr 15;26(3):335-355. doi: 10.1093/humupd/dmaa001. Hum Reprod Update. 2020. PMID: 32099997
-
Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.Arch Intern Med. 1998 Apr 13;158(7):777-81. doi: 10.1001/archinte.158.7.777. Arch Intern Med. 1998. PMID: 9554684
-
Prenatal and preconception population carrier screening for cystic fibrosis in Australia: where are we up to?Aust N Z J Obstet Gynaecol. 2014 Dec;54(6):503-9. doi: 10.1111/ajo.12255. Epub 2014 Oct 28. Aust N Z J Obstet Gynaecol. 2014. PMID: 25350764 Review.
Cited by
-
What can be offered to couples at (possibly) increased genetic risk?J Community Genet. 2012 Jul;3(3):167-74. doi: 10.1007/s12687-012-0105-1. Epub 2012 Jul 4. J Community Genet. 2012. PMID: 22760671 Free PMC article.
-
Understanding Genetic Screening: Harnessing Health Information to Prevent Disease Risks.Int J Med Sci. 2025 Jan 21;22(4):903-919. doi: 10.7150/ijms.101219. eCollection 2025. Int J Med Sci. 2025. PMID: 39991772 Free PMC article. Review.
-
Deciding on cystic fibrosis carrier screening: three citizens' juries and an online survey.Eur J Public Health. 2018 Oct 1;28(5):973-977. doi: 10.1093/eurpub/cky032. Eur J Public Health. 2018. PMID: 29562330 Free PMC article.
-
Primary care professionals' views on population-based expanded carrier screening: an online focus group study.Fam Pract. 2024 Aug 14;41(4):571-578. doi: 10.1093/fampra/cmad011. Fam Pract. 2024. PMID: 36722294 Free PMC article.
-
Responsible implementation of expanded carrier screening.Eur J Hum Genet. 2016 Jun;24(6):e1-e12. doi: 10.1038/ejhg.2015.271. Epub 2016 Mar 16. Eur J Hum Genet. 2016. PMID: 26980105 Free PMC article.
References
-
- American College of Obstetricians and Gynecology ACOG Committee opinion no. 432: spinal muscular atrophy. Obstet Gynecol. 2009;113(5):1194–1196. - PubMed
LinkOut - more resources
Full Text Sources